Poltreg S.A. (WSE:PTG)

Market Cap	157.38M +14.4%
Revenue (ttm)	n/a
Net Income	-27.31M
EPS	-5.86
Shares Out	5.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,187
Open	26.50
Previous Close	26.90
Day's Range	26.10 - 27.00
52-Week Range	16.00 - 32.70
Beta	0.82
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 9, 2026

About Poltreg

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1D; MOG CAR-Treg which is in phase I clinical trial for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; Multi-Edit/Allo MOG CAR-Treg which is in preclinical trial to treat multiple sclerosis, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis; and Antigen-specif...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 37
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: PTG

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 14, 2026

Data Sources Report a data error